ABC.L Regulatory News (ABC)

18 Jul 2006 07:00

ABCAM Plc18 July 2006 For immediate release 18 July 2006 ABCAM PLC ("Abcam" or "the Company") Appointment of Non-Executive Directors Abcam plc (AIM: ABC), the rapidly growing healthcare company that produces andmarkets antibodies via an online catalogue, is pleased to announce that witheffect from 1 July 2006 it has complemented its Board by the appointment of twoadditional Non-Executive Directors, Timothy George Dye and Mark John AlexanderWebster. Tim Dye, age 43, is currently Chairman and Chief Executive of William Ransom &Son plc, an AIM quoted healthcare company, as well as being a director of NobleTroy Ltd. Over the past six years, and through a series of successfulacquisitions, Tim Dye has led the transformation of William Ransom into one ofthe UK's largest natural healthcare groups. Prior to William Ransom, Tim Dyebuilt and ran privately held companies in automated meter reading, environmentalmanagement and property development. Mark Webster, age 44, is a highly experienced pharmaceutical executive who hasheld senior management positions at Bayer, Shire Pharmaceuticals and AbbottLaboratories. Most recently he was Senior Vice President, Head of GlobalStrategic Marketing and Licensing/ Acquisitions at Bayer Pharmaceuticals. Commenting on today's announcement, Jonathan Milner, Abcam's Chief ExecutiveOfficer, said: "I am pleased to welcome both Tim and Mark to Abcam's Board.Their experience, both in business and in the international pharmaceuticalindustry, will be of significant value to the Company as we continue to deliverour strategy of becoming the world's leading research antibody supplier." There are no further disclosures to be made in accordance with Schedule 2 (g) ofthe AIM rules. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Buchanan Communications + 44 (0) 20 7466 5000Mark CourtMary-Jane Johnson Notes for editors About Abcam Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.Abcam.com.The antibodies are sold almost entirely under the Abcam brandname. The Company'svision is to build the largest online antibody resource in the world while alsoensuring that the antibodies are of high quality and commercially viable. Abcamnow has an online catalogue of 23,000 products, most of which are antibodies,from over 200 suppliers supported by up-to-date and detailed technical datasheets, which are created by the Company. The Company currently employs 100staff. About antibodies Antibodies are proteins produced by white blood cells in response to theintroduction of a foreign body known as an antigen. Antibodies, which have awide variety of uses in research, diagnostics and therapeutics, are used bybioscientists in research into disease and into the human genome, where they areused to mark and identify specific cells and other living matter. The number ofhuman antibodies of use in research is potentially greater than one million. This information is provided by RNS The company news service from the London Stock Exchange